Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...

Biosimilars, once met with skepticism, are now an undeniable force in the global pharmaceutical market. As several ...

Philadelphia, USA-based Medicus Pharma and Boston-based biotech Helix Nanotechnologies have entered into a non-binding ...

A Seoul-based biotech company, founded to develop innovative therapies for neurodegenerative and immune disorders.

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate ...

A clinical‑stage biotech company developing gene therapies to treat common joint diseases such as knee osteoarthritis, which ...

Founded by experts in psychiatry and neuroscience to target neural circuits causally linked to disease, the company employs ...

Allogene Therapeutics, a US biotech developing allogeneic CAR T products for cancer and autoimmune disease, closed 12% lower ...

Chinese biotech Mabgeek Biotechnology has filed to go public in Hong Kong, seeking to raise funds to support development of ...

New York-based Spine BioPharma on Friday revealed disappointing results with its growth factor beta (TGF-β) antagonist, SB-01 ...